Related Topics
 

Bibliography and Other Relevant Articles


IPACTR

Altekruse SF, e. a. (2010). SEER Cancer Statistics Review, 1975-2007. 2009, from http://seer.cancer.gov/csr/1975_2007/.

Ballock RT, Wiesner GL, et al. Hemihypertrophy. Concepts and controversies. J Bone Joint Surg Am 79(11):1731-1738, 1997.

Birch JM, Hartley AL, et al. Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. Cancer Res 54(5):1298-1304, 1994.

Bisgaard ML, Fenger K, et al. Familial adenomatous polyposis (FAP): frequency, penetrance, and mutation rate. Hum Mutat 3(2):121-125, 1994.

Brandi ML, Gagel RF, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 86(12):5658-5671, 2001.

Bugg MF, Ribeiro RC, et al. Correlation of pathologic features with clinical outcome in pediatric adrenocortical neoplasia. A study of a Brazilian population. Brazilian Group for Treatment of Childhood Adrenocortical Tumors. Am J Clin Pathol 101(5):625-629, 1994.

Carney JA, Gordon H, et al. The complex of myxomas, spotty pigmentation, and endocrine overactivity. Medicine (Baltimore) 64(4):270-283, 1985.

Dehner LP, Hill DA. Adrenal cortical neoplasms in children: why so many carcinomas and yet so many survivors? Pediatr Dev Pathol 12(4): 284-291, 2009.

Ferrarini A, Auteri-Kaczmarek A, et al. Early occurrence of lung adenocarcinoma and breast cancer after radiotherapy of a chest wall sarcoma in a patient with a de novo germline mutation in TP53. Fam Cancer 10(2):187-192, 2011.

Li FP, Fraumeni JF Jr. Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Intern Med 71(4):747-752, 1969.

Li FP, Fraumeni JF Jr, et al. A cancer family syndrome in twenty-four kindreds. Cancer Res 48(18):5358-5362, 1988.

Libe R, Fratticci A, et al. Adrenocortical cancer: pathophysiology and clinical management. Endocr Relat Cancer 14(1):13-28, 2007.

Malkin D, Li FP, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250(4985):1233-1238, 1990.

Marx S, Spiegel AM, et al. Multiple endocrine neoplasia type 1: clinical and genetic topics. Ann Intern Med 129(6):484-494, 1998.

Michalkiewicz E, Sandrini R, et al. Clinical and outcome characteristics of children with adrenocortical tumors: a report from the International Pediatric Adrenocortical Tumor Registry. J Clin Oncol 22(5):838-845, 2004.

Michalkiewicz EL, Sandrini R, et al. Clinical characteristics of small functioning adrenocortical tumors in children. Med Pediatr Oncol 28(3):175-178, 1997.

Petitjean A, Mathe E, et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 28(6):622-629, 2007.

Pinto EM, Billerbeck AE, et al. Founder effect for the highly prevalent R337H mutation of tumor suppressor p53 in Brazilian patients with adrenocortical tumors. Arq Bras Endocrinol Metabol 48(5):647-650, 2004.

Pinto EM, Ribeiro RC, et al. TP53-Associated Pediatric Malignancies. Genes Cancer 2(4):485-490, 2011.

Pinto EM, Ribeiro RC, et al. Inherited germline TP53 mutation encodes a protein with an aberrant C-terminal motif in a case of pediatric adrenocortical tumor. Fam Cancer 10(1):141-146, 2011.

Ribeiro RC, Figueiredo B. Childhood adrenocortical tumours. Eur J Cancer 40(8):1117-1126, 2004.

Ribeiro RC, Pinto EM, et al. Familial predisposition to adrenocortical tumors: clinical and biological features and management strategies. Best Pract Res Clin Endocrinol Metab 24(3):477-490, 2010.

Ribeiro RC, Pinto EM, et al. The International Pediatric Adrenocortical Tumor Registry initiative: Contributions to clinical, biological, and treatment advances in pediatric adrenocortical tumors. Mol Cell Endocrinol 2011.

Ribeiro RC, Sandrini F, et al. An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. Proc Natl Acad Sci U S A 98(16):9330-9335, 2001.

Rodriguez-Galindo C, Figueiredo BC, et al. Biology, clinical characteristics, and management of adrenocortical tumors in children. Pediatr Blood Cancer 45(3):265-273, 2005.

Russell-Swetek A, West AN, et al. Identification of a novel TP53 germline mutation E285V in a rare case of paediatric adrenocortical carcinoma and choroid plexus carcinoma. J Med Genet 45(9):603-606, 2008.

Schteingart DE, Doherty GM, et al. Management of patients with adrenal cancer: recommendations of an international consensus conference. Endocr Relat Cancer 12(3):667-680, 2005.

Terzolo M, Angeli A, et al. Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med 356(23):2372-2380, 2007.

Trump D, Farren B, et al. Clinical studies of multiple endocrine neoplasia type 1 (MEN1). QJM 89(9):653-669, 1996.

Varley JM, McGown G, et al. Are there low-penetrance TP53 Alleles? evidence from childhood adrenocortical tumors. Am J Hum Genet 65(4):995-1006, 1999.

Wangberg B, Khorram-Manesh A, et al. The long-term survival in adrenocortical carcinoma with active surgical management and use of monitored mitotane. Endocr Relat Cancer 17(1):265-272, 2010.

West AN, Neale GA, et al. Gene expression profiling of childhood adrenocortical tumors. Cancer Res 67(2):600-608, 2007.

West AN, Ribeiro RC, et al. Identification of a novel germ line variant hotspot mutant p53-R175L in pediatric adrenal cortical carcinoma. Cancer Res 66(10):5056-5062, 2006.

Wieneke JA, Thompson LD, et al. Adrenal cortical neoplasms in the pediatric population: a clinicopathologic and immunophenotypic analysis of 83 patients. Am J Surg Pathol 27(7):867-881, 2003.